KPC Pharmaceuticals (SHA:600422) saw its net profit decline to 390.5 million yuan in the nine months ended Sept. 30 from 396.2 million yuan a year prior, parent China Resources Pharmaceutical Group (HKG:3320) said in an Oct. 25 bourse filing.
The drugmaker's revenue for the period fell to 5.46 billion yuan from 5.61 billion yuan in the year-ago period.
Shares of KPC Pharmaceuticals closed over 6% higher on Monday.
Price (HKD): $15.45, Change: $+0.94, Percent Change: +6.48%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.